

GLAXOSMITHKLINE PLC

Form 6-K

January 13, 2014

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending January 2014

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (the Plan) notified the Company and the under-mentioned persons on 13 January 2014 of the following increases in their notional interests in Ordinary Shares and American Depositary Shares (ADSs) at a price of 1599 pence per Ordinary Share and \$52.73 per ADS following the re-investment of dividends paid to shareholders on 9 January 2014.

Sir Andrew Witty	Acquisition of 1,463 Ordinary Shares under the personal contribution element of the Plan. Acquisition of 1,463 Ordinary Shares under the matching element of the Plan (Company contribution).
Mr S Dingemans	Acquisition of 525 Ordinary Shares under the personal contribution element of the Plan. Acquisition of 525 Ordinary Shares under the matching element of the Plan (Company contribution).
Dr M M Slaoui	Acquisition of 693 ADSs under the personal contribution element of the Plan. Acquisition of 693 ADSs under the matching element of the Plan (Company contribution).
Mr S M Bicknell	Acquisition of 220 Ordinary Shares under the personal contribution element of the Plan. Acquisition of 220 Ordinary Shares under the matching element of the Plan (Company contribution).
Mrs D P Connelly	Acquisition of 123 ADSs under the personal contribution element of the Plan. Acquisition of 123 ADSs under the matching element of the Plan (Company contribution).
Mr R G Connor	Acquisition of 60 Ordinary Shares under the personal contribution element of the Plan. Acquisition of 60 Ordinary Shares under the matching element of the Plan (Company contribution).
Mr W C Louv	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Acquisition of 102 ADSs under the personal contribution element of the Plan.

Acquisition of 102 ADSs under the matching element of the Plan (Company contribution).

Mr D S Redfern Acquisition of 346 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 346 Ordinary Shares under the matching element of the Plan (Company contribution).

Ms C Thomas Acquisition of 223 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 223 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr P C Thomson Acquisition of 11 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 11 Ordinary Shares under the matching element of the Plan (Company contribution).

Mr D E Troy Acquisition of 329 ADSs under the personal contribution element of the Plan.

Acquisition of 329 ADSs under the matching element of the Plan (Company contribution).

Dr P J T Vallance Acquisition of 738 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 738 Ordinary Shares under the matching element of the Plan (Company contribution).

Ms E Walmsley Acquisition of 293 Ordinary Shares under the personal contribution element of the Plan.

Acquisition of 293 Ordinary Shares under the matching element of the Plan (Company contribution).

The notional dividends accrued will be paid out in proportion to the percentage of the participant's deferred annual bonus holdings that will vest following the end of the relevant measurement period.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

Sonja Arsenić
Corporate Secretariat

13 January 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: January 13, 2014

By: SIMON BICKNELL

Simon Bicknell
Authorised Signatory for and on
behalf of GlaxoSmithKline plc